The purpose of this study is to determine whether intravenous immunoglobulin (IVIg) is an
effective intervention for patients with diabetes, peripheral neuropathy, and demyelination
on nerve conduction studies. All patients will receive both IVIg and placebo for 3 months
each, with a 3 month washout period in between.